Prognostic Significance of CEA, CA 19-9 and CA 72-4 Preoperative Serum Levels in Gastric Carcinoma

Marrelli, Daniele; Roviello, Franco; Stefano, Alfonso De; Farnetani, Maurizio; Garosi, Lorenzo; Messano, A; Pinto, Enrico

doi:10.1159/000012001

Cited by 136 publications

(116 citation statements)

References 13 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this correlation is still controversial, since in other reports, the positivity rate of CEA, CA 72-4, and CA 19-9 was higher in the diffuse type 7 . Nonetheless, other authors have also shown no correlation between tumor marker levels and the histology of gastric cancer 10 .…”

Section: Discussionmentioning

confidence: 90%

“…Previous studies of serum levels of CEA, CA 19-9, and CA 72-4 in gastric cancer have demonstrated that the positivity of these markers has a wide range of variation, from 14% to 42% for CEA 1-8, 10,20-22 , from 16% to 38.4% for CA 19-9 7,8,10,21,22 , and from 24.2% to 45.3% for CA 72-4 7,9,10,22 .…”

Section: Discussionmentioning

confidence: 98%

“…The discrimination of the lymph node status of the patients could have clinical applications for staging. CEA, CA 72-4, and CA 19-9 were considered markers of lymph node involvement in other reports 8,10,20 . Ikeguchi et al 9 found that CEA was a good indicator of lymph node metastasis, while CA 72-4 was a good predictor of peritoneal metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…Tumor markers can be used clinically for the monitoring of tumor recurrence and used as prognostic factors because higher levels have been observed in advanced disease [8][9][10] . The combined assay of preoperative serum levels of CEA, CA 19-9, and CA 72-4 has provided additional prognostic information for patients resected for gastric cancer; patients with preoperative positivity for one of these possible tumor markers have a high risk of recurrence, even in the early stages of gastric cancer 10 .…”

Section: Rejane Mattar Claudio Roberto Alves De Andrade Giovanni Mamentioning

confidence: 99%

“…The combined assay of preoperative serum levels of CEA, CA 19-9, and CA 72-4 has provided additional prognostic information for patients resected for gastric cancer; patients with preoperative positivity for one of these possible tumor markers have a high risk of recurrence, even in the early stages of gastric cancer 10 .…”

Section: Rejane Mattar Claudio Roberto Alves De Andrade Giovanni Mamentioning

confidence: 99%

See 4 more Smart Citations

Preoperative serum levels of ca 72-4, cea, ca 19-9, and Alpha-fetoprotein in patients with gastric cancer

et al. 2002

View full text Add to dashboard Cite

INTRODUCTION: The clinical importance of preoperative serum levels of CA 72-4, carcinoembryonic antigen (CEA), CA 19-9, and alpha-fetoprotein (AFP) was prospectively evaluated in 44 patients with gastric cancer. METHOD: The serum tumor marker levels were determined by commercial radioimmunoassay kits. Positivity for CA 72-4 (>4 U/mL), CEA (>5 ng/mL), CA 19-9 (>37 U/mL), and AFP (>10 ng/mL) were correlated according to the stage, histology, and lymph node metastasis. RESULTS AND DISCUSSION: CA 72-4 showed a higher positivity rate for gastric cancer (47.7%) than CEA (25%), CA 19-9 (25%), and AFP (0%). The combination of CA 72-4 with CEA and CA 19-9 increased the sensitivity to 61.4%. The positivity rates of CA 72-4 in patients at stages I and II (initial disease) and in patients at stages III and IV (advanced disease) were 9% and 60.6%, respectively (P < 0.005). No correlation was found between CEA and CA 19-9 levels and the stage of gastric cancer. There was a tendency of positivity for CA 72-4 to suggest lymph node involvement, but it was not significant (P = 0.075). Serum levels of tumor markers did not show a correlation with the histological types of gastric cancer. CONCLUSION: Preoperative serum levels of CA 72-4 provided a predictive value in indicating advanced gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Rejane Mattar Claudio Roberto Alves De Andrade Giovanni Mamentioning

confidence: 99%

Section: Rejane Mattar Claudio Roberto Alves De Andrade Giovanni Mamentioning

confidence: 99%

See 3 more Smart Citations

Preoperative serum levels of ca 72-4, cea, ca 19-9, and Alpha-fetoprotein in patients with gastric cancer

et al. 2002

View full text Add to dashboard Cite

show abstract

Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer

et al. 2015

View full text Add to dashboard Cite

Due to differences in natural history and therapy, clinical trials of patients with advanced pancreatic cancer have recently been subdivided into unresectable locally advanced pancreatic cancer (LAPC) and metastatic disease. We aimed to evaluate prognostic factors in LAPC patients who were treated with first-line chemotherapy and describe patterns of disease progression. Patients with LAPC who initiated first-line palliative chemotherapy, 2001–2011 at the BC Cancer Agency were included. A retrospective chart review was conducted to identify clinicopathologic variables, treatment, and subsequent sites of metastasis. Kaplan–Meier and Cox-regression survival analyses were performed. A total of 244 patients were included in this study. For the majority of patients (94.3%), first-line therapy was single-agent gemcitabine. About 144 (59%) patients developed distant metastatic disease and the most frequent metastatic sites included peritoneum/omentum (42.3%), liver (41%), lungs (13.9%), and distant lymph nodes (9%). Median overall survival (OS) for the entire cohort was 11.7 months (95% CI, 10.6–12.8). Development of distant metastases was associated with significantly inferior survival (HR 3.56, 95% CI 2.57–4.93), as was ECOG 2/3 versus 0/1 (HR 1.69, 95% CI 1.28–2.23), CA 19.9 > 1000 versus ≤1000 (HR 1.59, 95% CI 1.19–2.14) and female gender, (HR 1.57, 95% CI 1.19–2.08). In this population-based study, 41% of LAPC patients treated with first-line chemotherapy died without evidence of distant metastases. Prognostic factors for LAPC were baseline performance status, elevated CA 19.9, gender, and development of distant metastasis. Results highlight the heterogeneity of LAPC and the importance of locoregional tumor control.

show abstract

Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer

Cheng

Wang

Huang

et al. 2008

Intl Journal of Cancer

View full text Add to dashboard Cite

Complementary DNA microarrays have identified aberrantly expressed genes in patients with gastric cancer. One that encodes secretory leukocyte protease inhibitor (SLPI) is among the aberrantly expressed genes and is associated with metastasis in gastric cancers. We evaluated the potential of SLPI expression as a helpful biomarker for detection of gastric cancer. Tumor tissue and matching noncancerous mucosa were obtained from 60 patients immediately after gastric resection. SLPI expression levels were determined by Northern and Western blot tests and quantitativereverse transcriptase-polymerase chain reaction (Q-RT-PCR). Paraffin-fixed tumor tissues were used for immunohistochemistry study in 119 patients. A consistent result was obtained between all examinations except plasma SLPI. SLPI mRNA transcripts and protein were overexpressed in gastric cancer cells, and the depth of wall invasion was significantly greater in serosa-invading (T3 and T4) cancers compared to the serosa-free (T1 and T2) cancers. These enhanced expressions were significantly associated with lymph node metastasis, and were significantly higher in stages III and IV, and higher than those in stages I and II. Five-year survival of patients with lower expression of the SLPI gene was significantly better than among patients with a higher expression. To better understand the function of SLPI in human gastric cancer cells, isogenic SLPI overexpressing cell lines (AZ521) were prepared. The migratory and invasive abilities were increased 4.4-fold to 6.9-fold, or 3.0-fold to 4.1-fold, respectively, in SLPI-overexpressing cell lines. The results point to SLPI as a potential prognostic marker for gastric cancer and its function in cell invasion. ' 2008 Wiley-Liss, Inc.Key words: gastrointestinal neoplasms; SLPI protein, human; reverse transcriptase polymerase chain reaction; tumor markers Gastric cancer is the second most common cancer in the world. It is the fifth leading cause of cancer-related deaths in Taiwan 1 and, despite a declining incidence, it is similarly serious in Western countries. 2 Surgery is the only cure for gastric cancer; however, curative resection is not feasible for the many patients whose cancer is too far advanced when detected. 3 To improve the poor survival outcome and permit earlier diagnosis, there is a need for new and more sensitive prognostic indicators or tumor markers than those currently available, such as carcinoembryonic antigen and CA19-9. 4 Gastric cancer is divided into 2 histomorphologic types, ''intestinal-differentiated'' and ''diffuse-undifferentiated.'' 5,6 However, similar lesions may differ in biological aggressiveness and response to therapy. 7 The molecular events involved in development and progression of gastric cancer are complex, and involve multiple genes and steps that operate sequentially or in concert. 6 Risk factors for gastric cancer include genetic alterations, chromosomal instability and infection caused by the bacterium Helicobacter pylori. 8,9 Numerous biomarkers have contributed to our kn...

show abstract

Prognostic Significance of CEA, CA 19-9 and CA 72-4 Preoperative Serum Levels in Gastric Carcinoma

Cited by 136 publications

References 13 publications

Preoperative serum levels of ca 72-4, cea, ca 19-9, and Alpha-fetoprotein in patients with gastric cancer

Preoperative serum levels of ca 72-4, cea, ca 19-9, and Alpha-fetoprotein in patients with gastric cancer

Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer

Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer

Contact Info

Product

Resources

About